Effectiveness of sodium hyaluronate (Protad) application in endoscopic endonasal dacryocystorhinostomy

Abstract Objective To evaluate the effects of applying sodium hyaluronate solution (Protad) intraoperatively during endonasal dacryocystorhinostomy. Methods A retrospective medical record review of all 254 patients (254 eyes) who underwent endonasal dacryocystorhinostomy for nasolacrimal duct obstru...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian journal of ophthalmology 2017-04, Vol.52 (2), p.192-197
Hauptverfasser: Park, Jinhwan, MD, Lee, Joonsik, MD, PhD, Jang, Sungmin, MD, Lee, Hwa, MD, PhD, Chang, Minwook, MD, PhD, Park, Minsoo, MD, PhD, Baek, Sehyun, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 197
container_issue 2
container_start_page 192
container_title Canadian journal of ophthalmology
container_volume 52
creator Park, Jinhwan, MD
Lee, Joonsik, MD, PhD
Jang, Sungmin, MD
Lee, Hwa, MD, PhD
Chang, Minwook, MD, PhD
Park, Minsoo, MD, PhD
Baek, Sehyun, MD, PhD
description Abstract Objective To evaluate the effects of applying sodium hyaluronate solution (Protad) intraoperatively during endonasal dacryocystorhinostomy. Methods A retrospective medical record review of all 254 patients (254 eyes) who underwent endonasal dacryocystorhinostomy for nasolacrimal duct obstruction was performed. The success rates and postoperative complications of the Protad application group (105 eyes) and the control group (149 eyes) were compared. Results The Protad group had better anatomical (96.2% vs 86.6%, p = 0.010) and functional (93.3% vs 85.2%, p = 0.046) surgical success rates. Granuloma developed less frequently in the Protad group (11.4% vs 32.9%, p < 0.001). Regarding secondary outcomes, synechia was less frequent in the Protad group, but the difference was not statistically significant ( p = 0.283). Crust and infection rates were also lower in the Protad group (6.7% vs 11.4% for crust, 7.6% vs 8.1% for infection), but the difference was not statistically significant ( p = 0.203 and p = 0.899, respectively). The rate of revision surgery was significantly lower in the Protad group compared to the control group (1.9% vs 14.1%, p < 0.001). Granuloma had the largest effects on anatomical and functional surgical success (odds ratio, 72.221 for anatomical and 19.915 for functional). Conclusions The application of Protad effectively reduced postoperative granulation and enhanced surgical success rate after endonasal dacryocystorhinostomy. We suggest that Protad is a good nasal dressing material, especially for beginners in endoscopic surgery who work on Asian patients with narrow nasal cavities.
doi_str_mv 10.1016/j.jcjo.2016.08.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1893970491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0008418215300855</els_id><sourcerecordid>1893970491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-7260cb6ba629008b1c749f0e3376e5f6591619a0860efea7c206766b22d0ac2d3</originalsourceid><addsrcrecordid>eNp9kcFu1jAQhC1ERf8WXoADyrEckq6dxEkkhFRVpSBVaiXgbDn2WnVI7GAnlfL2OPyFAwdOO4eZ0e63hLylUFCg_HIoBjX4giVdQFsAhRfkQBta52XJ4SU5AECbV7Rlp-QsxgGgLJuKvyKnrK3qhnVwIObGGFSLfUKHMWbeZNFru07Z4ybHNXgnF8wuHoJfpH6fyXkerZKL9S6zLkOnfVR-tuq3dDLKMdNShc2rLS4-PFrn05y21-TEyDHim-d5Tr5_uvl2_Tm_u7_9cn11l6uK0iVvGAfV817ytBy0PVVN1RnAtDfH2vC6o5x2EloOaFA2igFvOO8Z0yAV0-U5uTj2zsH_XDEuYrJR4ThKh36NgrZd2TVQdTRZ2dGqgo8xoBFzsJMMm6Agdr5iEDtfsfMV0IrEN4XePfev_YT6b-QP0GT4cDRguvLJYhBRWXQKtQ2Js9De_r__4z9xNVqXkI8_cMM4-DW4xE9QEZkA8XX_8P5gWpdJ1XX5CzeoolM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1893970491</pqid></control><display><type>article</type><title>Effectiveness of sodium hyaluronate (Protad) application in endoscopic endonasal dacryocystorhinostomy</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Park, Jinhwan, MD ; Lee, Joonsik, MD, PhD ; Jang, Sungmin, MD ; Lee, Hwa, MD, PhD ; Chang, Minwook, MD, PhD ; Park, Minsoo, MD, PhD ; Baek, Sehyun, MD, PhD</creator><creatorcontrib>Park, Jinhwan, MD ; Lee, Joonsik, MD, PhD ; Jang, Sungmin, MD ; Lee, Hwa, MD, PhD ; Chang, Minwook, MD, PhD ; Park, Minsoo, MD, PhD ; Baek, Sehyun, MD, PhD</creatorcontrib><description>Abstract Objective To evaluate the effects of applying sodium hyaluronate solution (Protad) intraoperatively during endonasal dacryocystorhinostomy. Methods A retrospective medical record review of all 254 patients (254 eyes) who underwent endonasal dacryocystorhinostomy for nasolacrimal duct obstruction was performed. The success rates and postoperative complications of the Protad application group (105 eyes) and the control group (149 eyes) were compared. Results The Protad group had better anatomical (96.2% vs 86.6%, p = 0.010) and functional (93.3% vs 85.2%, p = 0.046) surgical success rates. Granuloma developed less frequently in the Protad group (11.4% vs 32.9%, p &lt; 0.001). Regarding secondary outcomes, synechia was less frequent in the Protad group, but the difference was not statistically significant ( p = 0.283). Crust and infection rates were also lower in the Protad group (6.7% vs 11.4% for crust, 7.6% vs 8.1% for infection), but the difference was not statistically significant ( p = 0.203 and p = 0.899, respectively). The rate of revision surgery was significantly lower in the Protad group compared to the control group (1.9% vs 14.1%, p &lt; 0.001). Granuloma had the largest effects on anatomical and functional surgical success (odds ratio, 72.221 for anatomical and 19.915 for functional). Conclusions The application of Protad effectively reduced postoperative granulation and enhanced surgical success rate after endonasal dacryocystorhinostomy. We suggest that Protad is a good nasal dressing material, especially for beginners in endoscopic surgery who work on Asian patients with narrow nasal cavities.</description><identifier>ISSN: 0008-4182</identifier><identifier>EISSN: 1715-3360</identifier><identifier>DOI: 10.1016/j.jcjo.2016.08.010</identifier><identifier>PMID: 28457290</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Adjuvants, Immunologic - administration &amp; dosage ; Administration, Topical ; Dacryocystorhinostomy - methods ; Female ; Follow-Up Studies ; Humans ; Hyaluronic Acid - administration &amp; dosage ; Internal Medicine ; Intraoperative Period ; Lacrimal Duct Obstruction - diagnosis ; Lacrimal Duct Obstruction - therapy ; Male ; Middle Aged ; Nasolacrimal Duct - surgery ; Natural Orifice Endoscopic Surgery - methods ; Ophthalmology ; Postoperative Complications - prevention &amp; control ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Canadian journal of ophthalmology, 2017-04, Vol.52 (2), p.192-197</ispartof><rights>Canadian Ophthalmological Society</rights><rights>2017 Canadian Ophthalmological Society</rights><rights>Copyright © 2017 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-7260cb6ba629008b1c749f0e3376e5f6591619a0860efea7c206766b22d0ac2d3</citedby><cites>FETCH-LOGICAL-c411t-7260cb6ba629008b1c749f0e3376e5f6591619a0860efea7c206766b22d0ac2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcjo.2016.08.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28457290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Jinhwan, MD</creatorcontrib><creatorcontrib>Lee, Joonsik, MD, PhD</creatorcontrib><creatorcontrib>Jang, Sungmin, MD</creatorcontrib><creatorcontrib>Lee, Hwa, MD, PhD</creatorcontrib><creatorcontrib>Chang, Minwook, MD, PhD</creatorcontrib><creatorcontrib>Park, Minsoo, MD, PhD</creatorcontrib><creatorcontrib>Baek, Sehyun, MD, PhD</creatorcontrib><title>Effectiveness of sodium hyaluronate (Protad) application in endoscopic endonasal dacryocystorhinostomy</title><title>Canadian journal of ophthalmology</title><addtitle>Can J Ophthalmol</addtitle><description>Abstract Objective To evaluate the effects of applying sodium hyaluronate solution (Protad) intraoperatively during endonasal dacryocystorhinostomy. Methods A retrospective medical record review of all 254 patients (254 eyes) who underwent endonasal dacryocystorhinostomy for nasolacrimal duct obstruction was performed. The success rates and postoperative complications of the Protad application group (105 eyes) and the control group (149 eyes) were compared. Results The Protad group had better anatomical (96.2% vs 86.6%, p = 0.010) and functional (93.3% vs 85.2%, p = 0.046) surgical success rates. Granuloma developed less frequently in the Protad group (11.4% vs 32.9%, p &lt; 0.001). Regarding secondary outcomes, synechia was less frequent in the Protad group, but the difference was not statistically significant ( p = 0.283). Crust and infection rates were also lower in the Protad group (6.7% vs 11.4% for crust, 7.6% vs 8.1% for infection), but the difference was not statistically significant ( p = 0.203 and p = 0.899, respectively). The rate of revision surgery was significantly lower in the Protad group compared to the control group (1.9% vs 14.1%, p &lt; 0.001). Granuloma had the largest effects on anatomical and functional surgical success (odds ratio, 72.221 for anatomical and 19.915 for functional). Conclusions The application of Protad effectively reduced postoperative granulation and enhanced surgical success rate after endonasal dacryocystorhinostomy. We suggest that Protad is a good nasal dressing material, especially for beginners in endoscopic surgery who work on Asian patients with narrow nasal cavities.</description><subject>Adjuvants, Immunologic - administration &amp; dosage</subject><subject>Administration, Topical</subject><subject>Dacryocystorhinostomy - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hyaluronic Acid - administration &amp; dosage</subject><subject>Internal Medicine</subject><subject>Intraoperative Period</subject><subject>Lacrimal Duct Obstruction - diagnosis</subject><subject>Lacrimal Duct Obstruction - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasolacrimal Duct - surgery</subject><subject>Natural Orifice Endoscopic Surgery - methods</subject><subject>Ophthalmology</subject><subject>Postoperative Complications - prevention &amp; control</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0008-4182</issn><issn>1715-3360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1jAQhC1ERf8WXoADyrEckq6dxEkkhFRVpSBVaiXgbDn2WnVI7GAnlfL2OPyFAwdOO4eZ0e63hLylUFCg_HIoBjX4giVdQFsAhRfkQBta52XJ4SU5AECbV7Rlp-QsxgGgLJuKvyKnrK3qhnVwIObGGFSLfUKHMWbeZNFru07Z4ybHNXgnF8wuHoJfpH6fyXkerZKL9S6zLkOnfVR-tuq3dDLKMdNShc2rLS4-PFrn05y21-TEyDHim-d5Tr5_uvl2_Tm_u7_9cn11l6uK0iVvGAfV817ytBy0PVVN1RnAtDfH2vC6o5x2EloOaFA2igFvOO8Z0yAV0-U5uTj2zsH_XDEuYrJR4ThKh36NgrZd2TVQdTRZ2dGqgo8xoBFzsJMMm6Agdr5iEDtfsfMV0IrEN4XePfev_YT6b-QP0GT4cDRguvLJYhBRWXQKtQ2Js9De_r__4z9xNVqXkI8_cMM4-DW4xE9QEZkA8XX_8P5gWpdJ1XX5CzeoolM</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Park, Jinhwan, MD</creator><creator>Lee, Joonsik, MD, PhD</creator><creator>Jang, Sungmin, MD</creator><creator>Lee, Hwa, MD, PhD</creator><creator>Chang, Minwook, MD, PhD</creator><creator>Park, Minsoo, MD, PhD</creator><creator>Baek, Sehyun, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Effectiveness of sodium hyaluronate (Protad) application in endoscopic endonasal dacryocystorhinostomy</title><author>Park, Jinhwan, MD ; Lee, Joonsik, MD, PhD ; Jang, Sungmin, MD ; Lee, Hwa, MD, PhD ; Chang, Minwook, MD, PhD ; Park, Minsoo, MD, PhD ; Baek, Sehyun, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-7260cb6ba629008b1c749f0e3376e5f6591619a0860efea7c206766b22d0ac2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adjuvants, Immunologic - administration &amp; dosage</topic><topic>Administration, Topical</topic><topic>Dacryocystorhinostomy - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hyaluronic Acid - administration &amp; dosage</topic><topic>Internal Medicine</topic><topic>Intraoperative Period</topic><topic>Lacrimal Duct Obstruction - diagnosis</topic><topic>Lacrimal Duct Obstruction - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasolacrimal Duct - surgery</topic><topic>Natural Orifice Endoscopic Surgery - methods</topic><topic>Ophthalmology</topic><topic>Postoperative Complications - prevention &amp; control</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Jinhwan, MD</creatorcontrib><creatorcontrib>Lee, Joonsik, MD, PhD</creatorcontrib><creatorcontrib>Jang, Sungmin, MD</creatorcontrib><creatorcontrib>Lee, Hwa, MD, PhD</creatorcontrib><creatorcontrib>Chang, Minwook, MD, PhD</creatorcontrib><creatorcontrib>Park, Minsoo, MD, PhD</creatorcontrib><creatorcontrib>Baek, Sehyun, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Jinhwan, MD</au><au>Lee, Joonsik, MD, PhD</au><au>Jang, Sungmin, MD</au><au>Lee, Hwa, MD, PhD</au><au>Chang, Minwook, MD, PhD</au><au>Park, Minsoo, MD, PhD</au><au>Baek, Sehyun, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of sodium hyaluronate (Protad) application in endoscopic endonasal dacryocystorhinostomy</atitle><jtitle>Canadian journal of ophthalmology</jtitle><addtitle>Can J Ophthalmol</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>52</volume><issue>2</issue><spage>192</spage><epage>197</epage><pages>192-197</pages><issn>0008-4182</issn><eissn>1715-3360</eissn><abstract>Abstract Objective To evaluate the effects of applying sodium hyaluronate solution (Protad) intraoperatively during endonasal dacryocystorhinostomy. Methods A retrospective medical record review of all 254 patients (254 eyes) who underwent endonasal dacryocystorhinostomy for nasolacrimal duct obstruction was performed. The success rates and postoperative complications of the Protad application group (105 eyes) and the control group (149 eyes) were compared. Results The Protad group had better anatomical (96.2% vs 86.6%, p = 0.010) and functional (93.3% vs 85.2%, p = 0.046) surgical success rates. Granuloma developed less frequently in the Protad group (11.4% vs 32.9%, p &lt; 0.001). Regarding secondary outcomes, synechia was less frequent in the Protad group, but the difference was not statistically significant ( p = 0.283). Crust and infection rates were also lower in the Protad group (6.7% vs 11.4% for crust, 7.6% vs 8.1% for infection), but the difference was not statistically significant ( p = 0.203 and p = 0.899, respectively). The rate of revision surgery was significantly lower in the Protad group compared to the control group (1.9% vs 14.1%, p &lt; 0.001). Granuloma had the largest effects on anatomical and functional surgical success (odds ratio, 72.221 for anatomical and 19.915 for functional). Conclusions The application of Protad effectively reduced postoperative granulation and enhanced surgical success rate after endonasal dacryocystorhinostomy. We suggest that Protad is a good nasal dressing material, especially for beginners in endoscopic surgery who work on Asian patients with narrow nasal cavities.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>28457290</pmid><doi>10.1016/j.jcjo.2016.08.010</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-4182
ispartof Canadian journal of ophthalmology, 2017-04, Vol.52 (2), p.192-197
issn 0008-4182
1715-3360
language eng
recordid cdi_proquest_miscellaneous_1893970491
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adjuvants, Immunologic - administration & dosage
Administration, Topical
Dacryocystorhinostomy - methods
Female
Follow-Up Studies
Humans
Hyaluronic Acid - administration & dosage
Internal Medicine
Intraoperative Period
Lacrimal Duct Obstruction - diagnosis
Lacrimal Duct Obstruction - therapy
Male
Middle Aged
Nasolacrimal Duct - surgery
Natural Orifice Endoscopic Surgery - methods
Ophthalmology
Postoperative Complications - prevention & control
Retrospective Studies
Treatment Outcome
title Effectiveness of sodium hyaluronate (Protad) application in endoscopic endonasal dacryocystorhinostomy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T11%3A24%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20sodium%20hyaluronate%20(Protad)%20application%20in%20endoscopic%20endonasal%20dacryocystorhinostomy&rft.jtitle=Canadian%20journal%20of%20ophthalmology&rft.au=Park,%20Jinhwan,%20MD&rft.date=2017-04-01&rft.volume=52&rft.issue=2&rft.spage=192&rft.epage=197&rft.pages=192-197&rft.issn=0008-4182&rft.eissn=1715-3360&rft_id=info:doi/10.1016/j.jcjo.2016.08.010&rft_dat=%3Cproquest_cross%3E1893970491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1893970491&rft_id=info:pmid/28457290&rft_els_id=S0008418215300855&rfr_iscdi=true